A Phase Ib/II Safety Trial of Nivolumab in Combination With Ipilimumab Administered in Participants With Chemotherapy-naive Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (CheckMate 955: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 955)

RetiradoFase 3ClinicalTrials.gov

ID: NCT03048136Tipo: INTERVENTIONALInicio: 9 de mar de 2018Fin estimado: 29 de sept de 2019

Traducción no disponible, mostrando original

Resumen

A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab

Descripción detallada

A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
\) Stage IV or recurrent non-Small cell lung cancer
\) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
\) Prior adjuvant or neoadjuvant chemotherapy for local, advanced disease allowed if completed at least 6 months prior to randomization

Criterios de exclusión

\) Known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma syndrome(ALK) translocations that are sensitive to targeted inhibitor therapy
\) Active, known or suspected autoimmune disease or HIV infection
\) Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
\) Untreated Central Nervous System metastases

Intervenciones

drug

Nivolumab

Specified dose on specified days

drug

Ipilimumab

Specified dose on specified days

Ubicaciones

Local Institution

Viedma, Río Negro Province, Argentina

Patrocinadores

PrincipalBristol-Myers Squibb

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase Ib/II Safety Trial of Nivolumab in Combination Wi... | EligiMed